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i
Summary: A highly sensitive and specific radioimmunoassay for the measurement of insulin-like growth
factor I (IGF I) has been developed. The IGF I concentrations were measured in sera of normal subjects,
patients with acromegaly, hypophysectomized patients and patients with hyperprolactinaemia. The results
were compared with the results obtained after measurement of IGF I in the sera of the same patients with
two commercially available radioimmunoassays for somatomedin-C.
^ IGF I was separated from its carrier protein using Sep-Pak C18 cartridges. The total recovery of IGF I by
t this method was about 100%. The in-house assay shows a high specificity for IGF I and a high sensitivity.
| As little äs 0.1 g/l of IGF I can be detected. Only a small amount of serum (25 ) is necessary for the
IGF I determination and a great number of serum samples (more than 100 per day) can be processed.
The mean immunoreactive IGFI concentration was 379 + 159 g/l in normal adult subjects,
3340 ± 1094 g/l in acromegalic patients, and 52 + 11 g/l in growth-hormone deficient patients. Patients
with hyperprolactinaemia had an IGF I concentration of 433 + 112 g/l.
j
j Die radioimmunologische Bestimmung des insulinähnlichen Wachstumsfaktors I (IGFI) bei Patienten mit
] Akromegalie, Wachstumshofmonmangel und Hyperprolactinämie
\ Vergleich der Daten mit zwei kommerziell erhältlichen Radioimmunoassays
Zusammenfassung: Wir entwickelten einen empfindlichen und spezifischen Radioimmunoassay zur Bestim-
mung des insulinähnlichen Wachstumsfaktors I (IGF I). Wir bestimmten die IGF I-Konzentration in Seren
von gesunden Personen, Patienten mit Akromegalie, hypophysektomierten Patienten und Patienten mit
Hyperprolactinämie und Verglichen die Daten mit den Daten, die wir aus der Bestimmung der IGF I-
, Konzentration derselben Seren mit zwei kommerziell erhältlichen Radioimmunoassays für Somatomedin-C
erhalten haben.
! Das IGFI wurde von seinem Trägerprotein über Sep-Pak C18-Säulen abgetrennt. Mit dieser Methode
i erreichten wir eine Wiederfindungsrate von fast 100%, Mit diesem Radioimmunoassay können weniger als
l 0,1 g/l IGF I nachgewiesen werden. Außerdem sind nur sehr geringe Serumvolumina (25 ) erforderlich,
um eine Bestimmung durchzuführen. Wir beobachteten eine durchschnittliche IGF I-Konzentration von
379 ± 159 g/l bei gesunden erwachsenen Personen, bei Patienten mit Akromegalie lag der Durchschnittswert
bei 3340 ± 1094 g/l und bei Patienten mit Wachstumshormonmangel bei 52 ± 11 g/l. Bei Patienten mit
Hyperprolaetinämie lagen die durchschnittlichen IGF I-Werte bei 433 ±
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Introduction
The insulin-like growth factors or somatomedins are
growth hormone-dependent polypeptides. They
stimulate sulphate incorporation into cartilage, they
have insulin-like activities and they stimulate growth
of cultured cells (1,2).
Apart from the Isolation on the basis of different
biological properties and the different purification
procedures, recent studies document that somato-
medin-C (SM-C), somatomedin-A (SM-A) and insul-
in-like growth factor I (IGF I) are chemically ident-
ical and indistinguishable in radioligand and biologi-
cal assay Systems (3,4). SM-C/IGFI measurement
has been used in screening for growth hormone defici-
ency and in contrast, high levels of SM-C/IGF I are
found in acromegaly.
During recent years, radioimmunoassays for this ana-
lyte have been developed, and radioimmunoassays
are now commercially available. The main problem
in measuring this analyte is the presence of a serum
binding protein for SM-C/IGF I. This serum binding
protein is only partially saturated with IGF I (5) and
consequently a radioimmunological determination of
IGF I in whole serum leads to several difficulties.
Therefore the conditions used for IGF I and SM-
C radioimmunoassays were different. Some authors
measured IGF I in whole serum under equilibrium
(6) or non-equilibrium conditions (7). Other groups
have measured IGF I after Separation of IGF I from
its binding protein(s) by gel filtration (8) or acid-
ethanol extraction (9).
This report describes the development of a highly
sensitive and specific radioimmunoassay for IGF I
and its application to sera of normal subjects, patients
with acromegaly and hypophysectomized patients.
IGF I was measured in sera of these patients after
Separation from its binding protein(s). The results
obtained with this assay were compared with the
results obtained after measurement of IGF I in the
sera of the same patients with two commercially
available radioimmunoassays for SM-C.
Purification of IGF I
IGF I was purifled s described previously (10). Lyophilized
human serum was extracted with. acid-ethanol. The extract
was precipitated with acetone-ethariol, and the precipitate was
chromatographed on a Sephadex G-50 column (K50/100, Phar-
macia) in 0.1 mol/1 acetic acid. The IGF I-contaiiiing fractions
from the Sephadex G-50 column wereffurther purifled by pre^
parative isoelectric focusing over a r nge between pH 3.0 and
pH 9.0. The IGF I used to prepare the immunogen contained
material which isofocused at a pl of 8.5 ± 0.2 and was free of
immunoreactive insulin.
The IGF I used for radioimmunoassay was purified from the
IGF I-containing fractions from Sephadex G-50 chromatogra-
phy by FPLC-reversed phase chromatography, using a Pep
RPC HR 5/5 column (Pharmacia, Uppsala).
lodination f IGF I
IGF I, purified by FPLC-reversed phase chromatography, was
iodinated by the chloramine-T method: 5 μg of IGF l were
dissolved in 50 μΐ of 0.1 mol/1 phosphate buffer, pH 7.4, then
added to 37 MBq Na125I; the reaction was started by the addib
tion of 20 μΐ of chloramine T (5 g/l 0.1 mol/1 phosphate buffer).
After 30 s the reaction was stopped by the addition of 100 jll
of sodium metabisulphite (2.4 g/l 0.1 mol/1 phosphate buffer)
and 100 μΐ of Kl (10 mg/1 0.1 mol/1 phosphate buffer). The
reaction mixture was chromatographed on a column of Sepha-
dex G-25 with 0.1 mol/1 phosphate buffer, pH 7.4, containing
2 g/l human serum albumin. Before use, 125I-labelled IGF I was
chromatographed on a column of Sephadex G-75 with the same
buffer. 95% of the radioactivity was precipitable by 100 g/l
trichloroacetic acid. The specific activity of 125I-labelled IGF I
was 5.55 — 7.4 MBq^g protein.
Production of antiserum
The antigen used for immunization was prepared by conjugat-
ing IGF I to bovine serum albumin using l-ethyl-3-(3-dimethyl-
aminopropyl)-carbodiimide s* the coupling agent. Bovine
serum albumin (3.8 mg) and IGF Ϊ preparation (3 mg) were
dissolved in 0.9ml of .l mol/1 phosphate buffer, pH 7.4. To
this solution, 0.1 ml of a l-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide solution (300 g/l phosphate buffer) was added
dropwise with stirring at 20 °C over 24 hours. The reaction
mixture was then dialysed against 0.15 mol/1 sodium chloride
for 16 hours.
Three Chinchilla rabbits weighing approximately 4 kg were im-
munized. For the first and second injection, each rabbit received
about 600 μg of the IGF I bovine serum albumin complex
emulsified in complete Freund?s adjuvant. The subseqment injec-
tions were carried out at 3-week intervals with 100μg of the
IGF I bovine serum albumin complex, emulsified in incomplete
Freund** adjuvant. Ten millilitres of blood were drawn from an
ear vein after 3 weeks and biweekly thereafter.
Materials and Methods
Pure IGF I and IGF II were kindly supplied by Dr. /. Zapf,
University of Z rich, SM-C by Dr. A. J. D'Ercole, University
of North Carolina, Chapel Hill. Human insulin was a gift from
Eli Lilly and Company, Indianapolis. Epidermal growth factor
and fibroblast growth factor were purchased from Serva, Hei-
delberg. Radioimmunoassays for SM-C were purchased from
Nichols Institute Diagnostics, San Juan Capistrano, California
92675 (kit A) and from Immuno Nuclear Corporation, Stillwa-
ter, Minnesota 55082 (kit B). Goat anti-rabbit IgG was
purchased from Miles Scientific, Bayer Diagnostics, Munich.
Extraction of serum
Twenty flve micr litres of each serum sample were acidified
with 0.5ml of 0.5 mol/1 HC1. The Sep-Pak C18 cartridge
(Waters Ass., Milford, M A 01757) was washed with methanol
and subsequently equilibrated with 0.5 mol/1 acetic acid. The
serum sample was applied to the cartridge and chromato-
graphed in 0.5 mol/1 acetic acid with a flow rate of 0.5 ml/naSn.
Finally IGF I was eluted with 5 ml of methanol. The methanol
was evaporated and the dried samples were then dissolved in
25 μΐ of assay buffer and used at different dilutions in the
radioimmunoassay. * *
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Radioimmunoassay of IGF I
The assay was carried out at 4°C in a phosphate/albumin
buffer, pH 7.5, containing 200 mg/1 protamine sulphate, 4.14
g/l sodium phosphate, 2.5 g/l bovine serum albumin, 3.72 g/l
EDTA and 0.2 g/i Na-azide. The final volume of the reaction
mixture was 500 μΐ. Extracted serum sample (50 μΐ) was added
to 100 μΐ of l : 10000 diluted IGF I antiserum. After 2 hours,
100 μΐ of 125I-labaled IGF I (~ 30000 counts/min) was added
and the mixture was incubated for another 20 hours at 4 °C,
followed by the addition of 100 μΐ of 0.1 mol/1 EDTA solution
and 200 μΐ of aqueous normal rabbit serum (volume fraction
0.02). After l hour, the second antibody (100 μΐ of goat anti-
rabbit gamma globulin serum, diluted l : 4 with assay buffer)
was added and the mixture was incubated for l hour at 4 °C.
Then 500 μΐ of a 60 g/l polyethylene glycol (Mr 6000-7500)
solution was added. After 5 min the tubes were centrifuged
(15 min, 3000 min"1 at 4 °C). The supernatant was poured off
and the precipitate was counted in a gamma counter (1290
Gamma-Trac, Tracor Analytic). Samples were assayed in tripli-
cate at two or more concentrations.
Patients
Most blood saraples were obtained between 8 and 11 a. m. The
108 normal adult subjects ranged in age from 24 to 65 years.
None was receiving medication at the time of sampling.
The 17 acromegalic patients had elevated basal immunoreactive
growth hormone levels which did not fall below 6 μg/l after the
oral administration of a 100 g glucose load. The six patients
with hyperprolactinaemia had elevated immunoassayable
serum prolactin levels (> 100 ug/1). The sera from 7 patients
after hypophysectomy had decreased basal serum concentra-
tions of immunoreactive growth hormone. The absence of
growth hormone was demonstrated in four hypophysectomized
patients.
Results
Characteristics of the antiserum to IGF I
Antibodies to IGF I were detectable in the serum of
two of the three immunized rabbits 6 weeks after the
first injection of IGF I. Nine weeks after the first
injection a f rther rise of the antibody titre was
observed, which remained constant during the follow-
ing immunization. The antiserum was used at a
l : 10000 dilution for the radioimm rioassay. At this
diluti n the antiserum bound 64% of the 125I-labelled
IGF I after correction for non-specific binding. With
the above incubation procedure s little s 0.1 μg/l of
IGE I can be detected and half-m ximal displacement
was observed with 0.6 μg/l of IGFI (fig. 1). Intra-
assay v riability, expressed s the cpefficient of Varia-
tion was 2.56%. Inter ssay v riability, determined by
measuring the same samples in 10 assays, was 8.28%.
Specificity of the RIA
Figure l shows the cross reactivities of IGF I (Ulm),
IGF I (Z rich), IGF II, somatomedin-C, human insu-
lin, epidermal growth factor and fibroblast growth
0.1 1
Insulin-like growth foctor Ι
Fig. 1. Competitive Inhibition of the binding of 125I-labeiled
IGF I to IGF I antiserum by unlabelled IGF I (o -o),
IGF I (Z rich) (o -p), SM-C (o -o), IGF II (Δ - Δ),
insulin (Δ — Δ), epidermal growth factor (α — α) and
fibroblast growth factor (&— -J T).
factor in the radioimm noassay. The cross reactivity
of IGF I (Ulm), IGF I (Z rich) and somatomedin-
C in the radioimm noassay was similar. No cross
reactivity was observed with IGF II, human insulin,
epidermal growth factor and fibroblast growth factor.
IGF I RIA in extracted serum
For our radioimm noassay IGFI was separated
from its earrier protein(s) by Sep-Pak C18 cartridges.
When serum was extracted using C18 cartridges the
mean IGFI concentration was 379 ±159 μg/l in
normal subjects, 3340 ± 1094 μg/l in acromegalic
patients, and 52 + 11 μg/l in growth-hormone defi-
cient patients (fig. 2). The serum IGF I concentration
in six patients with hyperprolactinaemia was 433 ±
Different dilutions of the extracted sera showed dis-
placement curves parallel to the Standard curve.
Table l shows the IGFI values in 10 sera after dif-
ferent extraction procedures. The different extraction
procedures were compared by measuring a total of
53 samples.
After gel chromatography of the same samples in 0.1
mol/1 acetic acid, the mean IGFI level in normal
subjects was lower (198 ± 48 μg/l). When serum was
extracted with acid-ethanol according to the method
described by Daughaday et al. (9), the IGF I values
were higher than those after gel chromatography.
After extraction with C18 cartridges, the mean IGF I
level was about 15% higher than after acid-ethanol
extraction.
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Healthy Hypophys- Acromegalic Adults with
adults ectomized adults hyperprolac
adults tinaemia
Tab. 1. Measurement of IGF I in various sera of normal adults













































Tab. 2. Assay incubation schemes.
Step
ieasurement of the IGF I level in sera of normal adults, Serum/standard (ul)
ypophysectomized patients, acromegalic patients and First antibody (ul)
atients with hyperprolactinaemia by the in-house s- Additional buffer (μΐ)
ly. IGF I was separated from its carrier protein with Preincubation h/ °C
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were dependent on the serum dilution. RT = room temperature
Comparison of the in-house RIA with two
commercial kits
The assay incubation schemes are shown in table 2
and the Standard curve characteristics, including
some intercept values, are demonstrated in table 3.
Table 4 shows SM-C/IGFI values, measured by the
different radioimmunoassays in sera of normal sub-
jects, acromegalic patients, hypophysectomized
patients and patients with hyperprolactinaemia.
The main difference in these assays was the fact
that the SM-C/IGF I concentration was measured in
wholet serum by kit A and in extracted serum by kit B
and by the in-house method. The serum was extracted
by Sep-Pak C18 cartridges in both radioimmunoas-
says. Furthermore, the SM-C/IGF I values were
stated s μg/l in the in-house method and s U/l in
kit A and s mol/1 in kit B.
The intra-assay variability, expressed s the coeffi-
cient of Variation was 3.97% in kit A and 6.86%
in kit B. The interassay variability, determined by
measuring the same samples in 6 assays, was 9.82%
for kit A and 10.24% for kit B.
The sensitivity of the assays, s defined by that quan-
tity of the Standard that reduced the maximal binding
of 125I-labelled SM-C/125I-labelled IGF I by 10%, was
4.0 U/l SM-C for kit A, 2.2 mol/1 for kit B and
0.09 μg/l for the inhouse radioimmunoassay. The
determination of SM-C with kit A was carried out
with 50 μΐ of a l : 20 dil ted unextracted serum.
Therefore between 100 and 200 U/l SM-C could be
detected.
Using kit A, which determined the SM-C levd in
whole serum, the SM-C level in,normal subjects was
between 400 U/l and 1800 U/l, in'acromegalic patients
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B = unbound, T = total, qpm = counts/min
Tab. 4. Measurement of IGF I in sera of normal adults, acro-
megalic patients, hypophysectomized patients and
patients with hyperprolactinaemia, using the in-house




























































it was between 4000 U/l and 6200 U/l, in hypophysec-
tomized patients it was between 190 U/l and 300 U/L
The serum SM-C values in patients with hyperprolac-
tinaemia were between 480 U/l and 1100 U/L
Using kit B, the SM-C level in normal subjects was
between 12.2 nmol/1 and 24.0 nmol/1, in acromegalic
patients it was between 60 nmol/1 and 1ί4 nmol/1,
in patients with hyperprolactinaemia between 12.4
nmol/1 and 23.4 nmol/1 and in hypophysectomized
patients between 5.8 nmol/1 and 8.0 nmol/1.
Discussion
This study preseiits a new radioimmunoassay for the
measurement of IGF L
The antibody in this assay has a great affinity for
IGF I and does not recognize IGF II, and is therefore
very specific.
The main problem encountered in the measurement
of IGF I in serum is the fact that IGF I is bound to
carrier proteins. Probably less than l % of total IGFs
circulate in a free form. Two size forms of carrier
protein have been recognized in human serum. About
80% of the IGF is bound to the larger form which
has a molecular weight of 150000. The rest of the
IGF is bound to a smaller form with a molecular
weight of about 40000 (11,12).
The binding of IGFs to carrier proteins is highly
specific and of high affinity. Apparent association
constants of 0.2—l nmol/1 have been described (13,
14, 15) which are comparable to the affinity of the
binding of IGF I to most of its binding sites on the
cell membrane.
Since the serum carrier protein is only partially satu-
rated with IGF I (5), the radioimmunological deter-
mination of IGF I in whole serum is complicated.
The labelled IGF I may compete with the unlabelled
IGF I not only for its binding sites to the antibody
but also for its binding to the carrier proteins. There-
fore the concentration of IGF I carrier proteins may
influence the results of the radioimmunoassay.
The values obtained for IGF I in whole serum with
our inhouse assay were dependent on the serum dilu-
tion. A similar observation has been described by
Daughaday et al. (9) and Zapfet al. (8).
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Therefore we decided to determine IGF I in extracted
serum using Sep-Pak C18 cartridges for the Separ-
ation of IGF I from its carrier proteins. However,
other methods for the Separation of IGF I from its
carrier proteins have been described.
Zapfet al. (8) separated their IGF I from its binding
protein by gel chromatography, Daughaday et al. (9)
extracted the serum with acid-ethanol befofe measur-
ing the IGF L The IGFI values, determined after
these Separation procedures, were different. The im-
munoreactive serum IGF I levels, measured by Zapf
et al. were about 30% lower than the IGF I levels.
measured by Daughaday et al. after acid-ethanol ex-
traction of the sera.
We tested these different Separation procedures and
found that after a Separation of IGF I from its carrier
protein by gel chromatography the measured IGF I
values were more than 40% lower than those deter-
mined after an acid-ethanol extraction. These differ-
ences are due to a great loss of IGFI.during gel
chromatography. The total recovery of exogenous
IGFI added to serum was 60 — 65%. Zapf et al.
reported a total recovery by gel chromatography of
74%, whereas Daughaday et al. described a total
recovery of 100% by acid-ethanol extraction. After
Separation of IGF I from its binding protein by Sep-
Pak C18 cartridges, our measured IGF I values were
~ 15% higher than those obtained after acid-ethanol
extraction. This may be due to a loss of IGF I during
our Separation procedure by acid-ethanol. The total
recovery after acid-ethanol treatment was ~ 90%,
whereas the total recovery by Sep-Pak C18 cartridges
was about 100%. On the basis of the excellent re-
covery by the cartridge procedure we conclude that
this method is superior to Sephadex chromatography.
The comparison of the in^house* radioimmünoassay
with kit A and kit B shows that the values of kit B
and the inJiouse method correlate with each other.
The few discrepancies may be due to the antibody or
the quality of the labelled or unlabelled IGF I itself.
The method used with kit A was described by Für-
lanetto et al. (7), who developed a method for IGF I/
SM-C in whole serum, using a serum pool (l U/l of
IGF I) äs Standard. Therefore, a direct comparison
of the in-house assay with this method is difficült.
Since the values were given in U/l, oidy their relation*
ship to each other may be examined.
Our present in^house assay shows a high specificity
for IGF I and a high sensitivity. As little äs 0.1 g/l
of IGF I can be detected. The üse of C18 cartridges
for the Separation of IGF I from its binding protein
makes it possible to process a small amount of serum
(25 ) and a great nümber of serum samples (more
than 100 per day). The assay is suitable for roütine
use.
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